Bioprojet SCR

Executive Summary

Bioprojet SCR is a privately-held French pharmaceutical company with over four decades of history in discovering and developing small molecule therapeutics. Operating through two divisions—Bioprojet PHARMA (development and commercialization) and Bioprojet BIOTECH (R&D)—the company focuses on transforming scientific innovation into patient care solutions, with a notable track record in central nervous system (CNS) research. While the company maintains a low public profile and lacks disclosed financials or pipeline details, its long-standing presence in the CNS space suggests a steady, albeit conservative, approach to drug development. The absence of recent disclosures or major partnerships limits visibility, but the company's established reputation in France and potential for niche innovation warrant cautious interest.

Upcoming Catalysts (preview)

• TBDRelease of Phase 2 data for undisclosed CNS candidate40% success
• TBDNew licensing or collaboration deal for small molecule pipeline50% success